Author: Neozene

Study: Millennials Expect to Spend More on Meds
October 16, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Sharon Klahr Coey The COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds. WPP’s global media group, Mindshare, began surveying consumers in mid-March to find out what people were thinking about the then-emerging pandemic. The finding? A lot of concerned consumers. But Mindshare also found that the more consumers worry about their health, the more they plan to spend on medications, Alexis Fragale, Mindshare’s director of consumer insights, said. Overall,

New FDA Vaccine Rules Could Nix Pre-Election COVID-19 Shot
October 8, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Eric Sagonowsky A weeks-long feud between the White House and FDA over COVID-19 vaccine guidelines took another turn Tuesday as the agency released vaccine recommendations despite efforts by the White House to keep them under wraps. The FDA advises two months of monitoring after patients’ final doses, which could thwart President Donald Trump’s desire for a shot before the election. As COVID-19 vaccines move closer to potential reviews at the FDA, experts with the agency last month prepared to publish a

Genentech Pays $200M for Vaccibody’s Phase 1 Cancer Vaccine
October 1, 2020
By Neozene

The following article originally appeared in FierceBiotech and was written by Nick Paul Taylor Genentech has secured a global license to neoantigen cancer vaccines developed by Vaccibody. The Roche subsidiary is set to hand over $200 million in upfront and near-term payments to access the fruits of Vaccibody’s efforts to overcome the limitations of cancer vaccines. Personalized cancer vaccines have consistently underwhelmed in the clinic but continue to generate interest. Genentech committed up to $310 million in upfront and near-term milestones to work with BioNTech on mRNA-based personalized cancer vaccines in 2016.